Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia
Повышенная экспрессия маркера ЭМП виментина ассоциирована с неблагоприятным клиническим исходом при остром миелоидном лейкозе
2018-06-20
SCID: 54.1/44ru8xm2
Discuss with AI
TCGA dataacute myeloid leukemiaepithelial-mesenchymal transitionoverall survivalvimentin overexpression
Figures from the paper
Abstract (AI)
BACKGROUND: Vimentin (VIM) is a type III intermediate filament that maintains cell integrity, and is involved in cell migration, motility and adhesion. When overexpressed in solid cancers, vimentin drives epithelial to mesenchymal transition (EMT) and ultimately, metastasis. The effects of its overexpression in AML are unclear. METHODS: In this study, we analyzed the TCGA data of 173 AML patients for which complete clinical and expression data were available. In this analysis, we assessed the association between VIM mRNA expression and patient's clinical and molecular characteristics including clinical outcome. RESULTS: VIM overexpression was associated with higher white blood count (< p = 0.0001). Patients with high VIM expression have worse overall survival (OS) and disease-free survival (DFS) compared with patients with low VIM expression (median OS; 7.95 months vs 19.2 months; p = 0.029). After age-stratification, high VIM expression was significantly associated with worse overall survival in older patients (age ≥ 60; median OS: 5.4 vs 9.9 months: p = 0.0257) but not in younger patients (age < 60). In stratification analysis according to cytogenetic status, high VIM expression was significantly associated with shorter OS (7.95 vs 24.6 months: p = 0.0102) in cytogenetically normal, but not in cytogenetic abnormal AML. CONCLUSIONS: Collectively, the data indicate that overexpression of the EMT marker vimentin is associated with poor clinical outcome in older patients with cytogenetically normal AML; and therefore may play a role in this disease.
Key Findings
1
Among patients with cytogenetically normal AML, high VIM expression predicted shorter overall survival, 7.95 versus 24.6 months (p = 0.0102), whereas this association was not observed in cytogenetically abnormal AML.
2
High VIM expression was associated with worse overall and disease-free survival; median overall survival was 7.95 versus 19.2 months for low expression (p = 0.029).
3
TCGA analysis of 173 AML patients found that VIM mRNA overexpression was associated with significantly higher white blood cell counts (p < 0.0001).
4
The adverse prognostic association of high VIM expression was significant in patients aged 60 years or older, but not in younger patients.
5
Vimentin overexpression may contribute to poor clinical outcomes particularly in older patients with cytogenetically normal AML.
Research Object
Acute myeloid leukemia patients, particularly older patients with cytogenetically normal AML
Research Subject
The association of VIM/vimentin overexpression with clinical and molecular characteristics, overall survival, and disease-free survival
Publication Details
Publication Date
2018-06-20
Journal
Publisher
ISSN
Cited by
156
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest